eligibility_summary
Eligible: advanced nonsquamous NSCLC, prior-therapy AEs recovered to ≤Grade1, controlled HBV (on antivirals, undetectable), HCV (undetectable), or HIV (on ART), life expectancy ≥3 months. Exclude: squamous histology, other cancer unless curatively treated ≥3y, ≥Grade2 neuropathy, severe ocular surface disease, IBD, significant/uncontrolled cardio/cerebrovascular disease, RT <2 wks or lung RT >30 Gy/6 mo or RT toxicities needing steroids, live vaccine <30d, CNS mets, active infection, pneumonitis/ILD, HIV with Kaposi’s/MCD, concurrent HBV+HCV, prior allogeneic transplant, unresolved major surgery.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 randomized, open-label trial in EGFR-mutated, advanced nonsquamous NSCLC after progression on EGFR TKIs. Interventions: Sacituzumab tirumotecan (MK-2870/SKB264), a TROP2-targeting antibody–drug conjugate with a topoisomerase I inhibitor payload, vs pemetrexed + carboplatin. Mechanisms: MK-2870 binds TROP2 on tumor cells, is internalized, and releases a camptothecin-derived topo I inhibitor to induce DNA damage and cell death (potential bystander effect). Comparator: Pemetrexed is an antifolate inhibiting thymidylate synthase, DHFR, and GARFT, Carboplatin is a platinum agent creating DNA crosslinks. Targets/pathways: TROP2+ tumor cells, DNA replication via topo I, folate-dependent nucleotide synthesis, DNA crosslink repair/apoptosis. Supportive meds (H1/H2 blockers, acetaminophen, dexamethasone, steroid mouthwash) mitigate infusion reactions/mucositis.